The Effects of Daily-Living Risks on Breast Cancer-Related Lymphedema.

BACKGROUND: Conventional advice to reduce the risk of breast cancer-related lymphedema (BCLE) suggests avoidance of daily-living risks, and limited research has investigated these risks. OBJECTIVE: This study aimed to examine the occurrence, patterns, and effects of daily-living risks on BCLE. METHODS: A cross-sectional design was used to collect data from 567 patients at a metropolitan cancer center in the United States. The Lymphedema Risk-Reduction Behavior Checklist was used to assess the occurrence of 11 daily-living risks. Descriptive, regression, and factor analyses were performed. RESULTS: Significant odds of BCLE were associated with infection (odds ratio [OR] 2.58, 95% confidence interval [CI] 1.95-3.42), cuts/scratches (OR 2.65, 95% CI 1.97-3.56), sunburn (OR 1.89, 95% CI 1.39-3.56), oil splash or steam burns (OR 2.08, 95% CI 1.53-3.83), and insect bites (OR 1.59, 95% CI 1.18-2.13). The daily-living risks were clustered into factors related to skin trauma and carrying objects. Skin trauma risk was significantly associated with BCLE (B = 0.539, z = 3.926, OR 1.714, 95% CI 1.312-2.250; p < 0.001). Having three, four, or five skin trauma risks significantly increased the odds of BCLE to 4.31, 5.14, and 6.94 times, respectively. The risk of carrying objects had no significant or incremental effects on BCLE. CONCLUSION: Complete avoidance of daily-living risks is challenging given 52.73% of patients incurred more than five daily-living risks. Our study findings underscore the importance of 'what to do' strategies to minimize infection and skin trauma.

Lymphatic pain in breast cancer survivors: An overview of the current evidence and recommendations.

Among the 7.8 million women with breast cancer worldwide, at least 33% to 44% of them are affected by lymphatic pain. Lymphatic pain refers to co-occurring pain (e.g., pain, aching or soreness) and swelling. Pharmacological approaches, such as the uses of NSAIDS, opioids, antiepileptics, ketamine and lidocaine, have very limited effects on lymphatic pain. Limited research in this field has made it difficult for patients and clinicians to differentiate lymphatic pain from other types of pain. Precision assessment to distinguish different types of pain is essential for finding efficacious cure for pain. Innovative behavioral interventions to promote lymph flow and reduce inflammation are promising to reduce lymphatic pain. The goal of this review is to provide a comprehensive understanding of lymphatic pain through research evidence-based knowledge and insights into precision assessment and therapeutic behavioral intervention for lymphatic pain.